Rehan Verjee and the education of a second act

In October 2023, Rehan Verjee had a small problem with a large announcement. The original LinkedIn post introducing Precede Biosciences had disappeared, taking the posts linked to it along for the ride. A company could spend years preparing to introduce itself and still find the internet had misplaced the introduction. Verjee posted again.

He thanked the people who had offered encouragement. He acknowledged prospective collaborators and people interested in joining the team. He supplied fresh links. There was a new milestone to announce, too. The company was getting on with its work, and its co-founder was getting on with the practical business of making sure people could find it.

The episode is a useful place to meet him. Before Precede, Verjee had spent 17 years at Merck KGaA. He had run a country operation, held global strategy responsibilities, and become president of EMD Serono. By 2023, he was helping introduce a company built with academic founders and venture investors. The scale had changed. Some of the chores remained wonderfully ordinary.

The useful inconvenience of knowing both sides

Verjee’s education began at Oxford, where he studied Molecular and Cellular Biochemistry and earned a master’s degree. He joined Merck KGaA in 2004. His working education then carried him through several parts of the organization: first medical affairs, then development, then commercial responsibilities, and eventually executive leadership encompassing research and commercial decisions.

In his senior strategy role, he also co-chaired the R&D development committee and chaired major global alliances. That added an institutional dimension to the job: decisions had to be made with other leaders and organizations, across a portfolio of competing priorities. The title on a business card gives little indication of how many different conversations it can require.

That sequence matters because each role exposes a different part of the same enterprise. A research decision makes a claim about what might be possible. A commercial decision asks what the organization can deliver and support. When the same executive has responsibilities on both sides, the conversation becomes harder to divide into tidy departmental speeches.

It is tempting to compress a career like that into the word “experienced.” The more useful detail is the variety of experience. Verjee’s later responsibilities included portfolio strategy, business development, alliances, and operating leadership. These are different kinds of work. Each brings its own deadlines, evidence, and consequences. An organization chart can make them look more separate than they are.

“more is not always better”

Rehan Verjee, January 2025

His own compact observation offers a clue to how he discusses complexity. In a 2025 interview, he argued for choosing an approach according to its purpose, rather than assuming that adding more components improves it. Applied to company building, the thought is a useful question: what does this addition actually help the organization do?

Canada, then the larger map

Before his global executive appointments, Verjee led the Canadian operations of EMD Serono as managing director. Country leadership gives an executive a defined business to run. Decisions have to survive contact with a particular market, a particular workforce, and a particular set of operating requirements. A global ambition still needs someone to make the local machinery function.

In October 2015, he joined Merck KGaA’s executive committee as Chief Marketing and Strategy Officer. His remit expanded to global franchises and strategic functions, including business development. The move brought him from responsibility for a country business into decisions spanning a broader portfolio. Strategy acquired a larger map, with more people depending on how it was drawn.

Then, effective September 1, 2018, he became President of EMD Serono and Global Head of Innovative Medicine Franchises. He would lead the business in the United States and Canada while retaining global responsibilities. The appointment also involved a physical move: from Germany to the company’s American headquarters in Rockland, Massachusetts.

The geography gives this progression some texture. Canada, Germany, and Massachusetts were working settings in the same career. His responsibilities also extended to major markets including the United States, the European Union, China, and Japan. Running across borders requires coordination; a decision made in one room has to become usable in several others.

A departure with a destination still offstage

On February 4, 2021, Merck KGaA announced that Verjee had chosen to leave to pursue an outside opportunity. His executive tenure concluded in March. The announcement credited his 17 years with the company and named Andrew Paterson as his successor. The next opportunity was still awaiting its public introduction.

A departure announcement is an oddly narrow document for such a substantial change. It supplies a date, a successor, and a courteous description of service. The person leaving takes something less easily itemized: familiarity with decisions that worked, decisions that required revision, and the distance between approving a plan and making it happen.

By June 2021, he had also joined the board of Tyra Biosciences. His public roles came to include the Massachusetts Biotechnology Council, known as MassBio. These appointments put him in another relationship to an organization: helping oversee its direction as a director, alongside the work of running a company himself.

Four founders, different kinds of preparation

Precede brought Verjee together with Sylvan Baca, Toni Choueiri, and Matthew Freedman, three academic co-founders associated with Dana-Farber. The company was co-founded through 5AM Ventures’ 4:59 Initiative. Its early backing included 5AM Ventures and Binney Street Capital. The founding arrangement joined scientific work, investment, and operating experience.

That division of preparation deserves attention. A company built around specialized research needs people who understand the work itself. It also needs people who can organize a business around it. Verjee arrived with a background in large organizations; his co-founders brought their own academic careers. The shared enterprise gave those different histories a common set of responsibilities. That makes the founding team a useful unit for understanding the company. Verjee’s title identifies who leads it; the other founders’ careers help explain how it came to exist. Both belong in the story of its beginning.

In January 2022, Bedford Group Transearch announced his appointment to its North American advisory board. Its description of his earlier career included responsibility for more than $2 billion in profit-and-loss leadership and organizations exceeding 1,000 employees. Those figures describe the scale of his previous operating work. A new company asks that experience to function in a different setting.

In an established enterprise, much of the organization exists before a leader arrives. In a young company, choices about colleagues, partnerships, and priorities help create the organization itself. A founder’s past can inform those choices. It cannot make them automatically. The names attached to Precede’s founding also make clear that this was a collective beginning. Baca, Choueiri, Freedman, Verjee, and the company-creation team brought different contributions. Following the executive’s path helps explain one part of that arrangement without turning the entire company into a solo performance. Precede gave Verjee another place to exercise judgment, with a different set of resources around him.

The launch that needed a second post

Precede emerged publicly on October 5, 2023, disclosing $57 million in backing since inception. Its Series A had been co-led by 5AM Ventures and Lilly Asia Ventures. Other participants included Illumina Ventures, Bristol Myers Squibb, Osage University Partners, and Qatar Investment Authority. The company’s introduction brought its team and its work into public view.

Then came the vanished launch post and the repost. Verjee’s response kept the conversations attached to the announcement alive: thanks for the encouragement, an invitation to discuss collaboration, a route for people considering a role. The anecdote needs no heroic interpretation. It is simply an executive attending to people who had taken the trouble to respond.

“The most important one to emphasize is strategic clarity.”

Rehan Verjee, January 2025

When asked about competitive positioning in 2025, he emphasized clarity of purpose and the possibility of building a revenue-generating business able to sustain itself. That is a concrete ambition for a founder. A purpose needs a working organization behind it; the organization needs a way to keep paying for the work.

The arithmetic of another beginning

On January 12, 2026, Precede announced $83.5 million in financing. The total consisted of $63.5 million in Series B equity and a $20 million strategic credit facility. Keeping the two components visible makes the announcement easier to understand. Equity and a credit facility are different instruments, even when they share a headline.

The announcement also brought a governance change: Wouter Meuleman, a founding team member and partner at Illumina Ventures, would join the board. Capital and board composition are part of the same company-building story. One concerns resources; the other concerns who participates in overseeing their use.

Precede launched Precede Bio Insight in April 2026. By October, the company was announcing another conference presentation in Madrid. For Verjee, the calendar now contained the continuing milestones of an operating company. Public emergence had been one date. Running the business meant the dates kept arriving.

A smaller company, a fuller job

His current roles place him inside several kinds of institution: a founder-led company, a public company board, and a regional industry organization. The common thread is responsibility for how organizations develop. The scale and the seat at the table change what that responsibility requires.

There is an appealingly practical continuity in this second act. The Oxford graduate who crossed functions and countries now works with co-founders, colleagues, investors, and directors to build a business. Seventeen years supplied a substantial apprenticeship. Founding added a fresh job description. And when the introduction vanished, he still had to sit down and post it again.